# Semaglutide FLOW trial: kidney disease in type 2 diabetes

Source: https://pepvault.app/research/semaglutide-flow-2024

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Semaglutide](https://pepvault.app/research#semaglutide)

Randomized trial · people

# Semaglutide: 24% lower risk of major kidney events in FLOW

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

For people with type 2 diabetes and chronic kidney disease, this large trial links semaglutide to fewer serious kidney events and fewer deaths from heart causes than placebo over a median of 3.4 years.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 3533
- **Published:** 2024
- **Journal:** N Engl J Med

## What they tested

The team tested whether weekly semaglutide lowers the risk of kidney failure, heart-related death and other serious outcomes in people with both type 2 diabetes and chronic kidney disease.

## How the study was done

A randomized, placebo-controlled trial in 3533 people with type 2 diabetes and chronic kidney disease, who got either a 1.0 mg weekly semaglutide shot under the skin or placebo (a dummy shot). Median follow-up was 3.4 years, and the trial was stopped early on the advice given at a planned interim analysis.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

The main outcome combined kidney failure, a drop of at least 50% in eGFR (an estimate of how well the kidneys filter blood), and death from kidney or heart causes. It happened 331 times in the semaglutide group and 410 times in the placebo group, a 24% lower risk (hazard ratio 0.76; 95% CI 0.66 to 0.88). Death from heart and blood vessel causes was also lower (hazard ratio 0.71), as were major cardiovascular events (hazard ratio 0.82) and death from any cause (hazard ratio 0.80). eGFR fell more slowly each year with semaglutide, by 1.16 ml per minute per 1.73 m2, and serious side effects were reported in 49.6% of the semaglutide group versus 53.8% of the placebo group.

## What it doesn’t show

The trial included only people with type 2 diabetes and chronic kidney disease within set eGFR and urine albumin ranges, tested a single 1.0 mg dose, and was stopped early. It was funded by Novo Nordisk.

## The paper

Perkovic et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024.

- [PubMed (PMID 38785209)](https://pubmed.ncbi.nlm.nih.gov/38785209/)
- [The paper (DOI 10.1056/NEJMoa2403347)](https://doi.org/10.1056/NEJMoa2403347)
- [ClinicalTrials.gov (NCT03819153)](https://clinicaltrials.gov/study/NCT03819153)

## The compound

- [Semaglutide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

## With this study

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [All 20 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Semaglutide

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026) Randomized trial · people · 2026
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026) Randomized trial · people · 2026
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026) Randomized trial · people · 2026
- [Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetes](https://pepvault.app/research/semaglutide-adjust-t1d-2025) Randomized trial · people · 2025
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025) Randomized trial · people · 2025
- [Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks](https://pepvault.app/research/semaglutide-sanyal-2025) Randomized trial · people · 2025
- [Every study on Semaglutide](https://pepvault.app/research#semaglutide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [All 20 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Semaglutide](https://pepvault.app/research#semaglutide)

## The library

- [Semaglutide](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
